MedDataX Logo

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

NCT ID: NCT00141388

Last Updated: 2009-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

455 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-07-31

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141336

Seizure Disorder, Partial
COMPLETED PHASE3

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141245

Seizure Disorder, Partial
COMPLETED PHASE3

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00150293

Seizure Disorder, Partial
COMPLETED PHASE3

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

NCT00143143

Epilepsies, Partial Epilepsy, Complex Partial
COMPLETED PHASE3

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

NCT00141414

Epilepsy, Partial
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seizure Disorder, Partial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria

* Cannot have absence seizures.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Little Rock, Arkansas, United States

Site Status

Pfizer Investigational Site

Los Angeles, California, United States

Site Status

Pfizer Investigational Site

Pasadena, California, United States

Site Status

Pfizer Investigational Site

Gainesville, Florida, United States

Site Status

Pfizer Investigational Site

Gainesville, Florida, United States

Site Status

Pfizer Investigational Site

Miami, Florida, United States

Site Status

Pfizer Investigational Site

Plantation, Florida, United States

Site Status

Pfizer Investigational Site

Spring Hill, Florida, United States

Site Status

Pfizer Investigational Site

Tallahassee, Florida, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Springfield, Illinois, United States

Site Status

Pfizer Investigational Site

Springfield, Illinois, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Iowa City, Iowa, United States

Site Status

Pfizer Investigational Site

Kansas City, Kansas, United States

Site Status

Pfizer Investigational Site

Kansas City, Kansas, United States

Site Status

Pfizer Investigational Site

Louisville, Kentucky, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Greenbelt, Maryland, United States

Site Status

Pfizer Investigational Site

Boston, Massachusetts, United States

Site Status

Pfizer Investigational Site

Boston, Massachusetts, United States

Site Status

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Site Status

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Site Status

Pfizer Investigational Site

Saint Paul, Minnesota, United States

Site Status

Pfizer Investigational Site

Chesterfield, Missouri, United States

Site Status

Pfizer Investigational Site

Columbia, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Lebanon, New Hampshire, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Cleveland, Ohio, United States

Site Status

Pfizer Investigational Site

Columbus, Ohio, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Nashville, Tennessee, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Bennington, Vermont, United States

Site Status

Pfizer Investigational Site

Edmonton, Alberta, Canada

Site Status

Pfizer Investigational Site

Edmont, Alberta, Canada

Site Status

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Site Status

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Site Status

Pfizer Investigational Site

London, Ontario, Canada

Site Status

Pfizer Investigational Site

Ottawa, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1008-010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.
NCT00141427 COMPLETED PHASE4
Pregabalin Epilepsy Add-On Trial
NCT00141258 COMPLETED PHASE3
Once-A-Day Pregabalin For Partial Seizures
NCT01262677 COMPLETED PHASE3
Pregabalin In Partial Seizures Extension Study
NCT00143130 COMPLETED PHASE3
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
NCT00596466 COMPLETED PHASE3
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
NCT00524030 TERMINATED PHASE3
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281 COMPLETED PHASE1/PHASE2
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
NCT00280059 COMPLETED PHASE3
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
NCT00448916 COMPLETED PHASE3
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
NCT00407797 TERMINATED PHASE4
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306 COMPLETED PHASE3
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
NCT02072824 COMPLETED PHASE3
An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
NCT00372528 TERMINATED PHASE3
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
NCT01389596 COMPLETED PHASE3
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611 COMPLETED PHASE4
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures
NCT01147003 COMPLETED PHASE2
Clinical Study With Lyrica In Patients Suffering From Epilepsy
NCT00922987 COMPLETED
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
NCT01747915 COMPLETED PHASE3
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00288639 COMPLETED PHASE4
Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
NCT00684424 COMPLETED
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
NCT01167335 WITHDRAWN PHASE2
Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline
NCT01309074 WITHDRAWN PHASE4
Phase II BGG492 Capsule Extension for Partial Epilepsy
NCT01338805 COMPLETED PHASE2
Open-label Extension to Protocol 1042-0600
NCT00512317 COMPLETED PHASE2
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
NCT01422720 COMPLETED PHASE3